Summary: In 6522 patients hospitalised for acute myocardial infarction and at risk of heart failure, empagliflozin 10 mg started within 14 days of admission did not significantly reduce first heart failure hospitalisation or death from any cause compared with placebo (8.2% vs 9.1%; hazard ratio 0.90; 95% CI 0.76 to 1.06; p=0.21) over a median of 17.9 months. First heart failure hospitalisation was less frequent (3.6% vs 4.7%), but death from any cause was not.
PICO Summary
| Element | Detail |
|---|---|
| Population | 6522 patients hospitalised for acute myocardial infarction and at risk of heart failure; event-driven, double-blind, randomised, placebo-controlled trial; median follow-up 17.9 months. |
| Intervention | Empagliflozin 10 mg daily added to standard care within 14 days of admission (n=3260). |
| Comparison | Placebo added to standard care (n=3262). |
| Outcome | First heart failure hospitalisation or death from any cause: 267 (8.2%) vs 298 (9.1%); 5.9 vs 6.6 events per 100 patient-years; HR 0.90 (95% CI 0.76 to 1.06); p=0.21. First heart failure hospitalisation: 118 (3.6%) vs 153 (4.7%); HR 0.77 (95% CI 0.60 to 0.98). Death from any cause: 169 (5.2%) vs 178 (5.5%); HR 0.96 (95% CI 0.78 to 1.19). Adverse events were consistent with the known safety profile and similar in the two groups. |
Expert Commentary
My verdict is neutral. EMPACT-MI was a large, event-driven trial, and it did not meet its primary endpoint. Among 6522 patients at risk of heart failure after acute myocardial infarction, first heart failure hospitalisation or death from any cause occurred in 8.2% on empagliflozin and 9.1% on placebo over a median of 17.9 months (hazard ratio 0.90; 95% CI 0.76 to 1.06; p=0.21). First heart failure hospitalisation was less frequent with empagliflozin (3.6% against 4.7%; hazard ratio 0.77; 95% CI 0.60 to 0.98), in keeping with what the class does elsewhere, but death from any cause was unchanged (5.2% against 5.5%; hazard ratio 0.96; 95% CI 0.78 to 1.19). The limitation in reading this is that the hospitalisation result is one component of a primary outcome that failed, so it is hypothesis-generating and cannot be claimed as a proven benefit. Adverse events were similar in the two groups. The trial was funded by the manufacturers. Can I use this with my patients? Not as routine treatment after myocardial infarction. Where a patient has diabetes, heart failure or chronic kidney disease, empagliflozin is indicated for those reasons and can be started in this setting. For others, I would wait for evidence that early treatment prevents more than hospital admissions.
References
Butler J, Jones WS, Udell JA, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390(16):1455-1466. doi:10.1056/NEJMoa2314051. PMID: 38587237.

